STOCK TITAN

[6-K] NOVARTIS AG Current Report (Foreign Issuer)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Analyzing...



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
 
Report on Form 6-K dated February 4, 2026
(Commission File No. 1-15024)
 

 
Novartis AG
(Name of Registrant)
 
 
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
 


 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F: ☒
   
Form 40-F: ☐
 


 






Exhibits:

99.1 Annual Report 2025
99.2 Report on Nonfinancial Matters 2025


SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Novartis AG
   
     
Date: February 4, 2026
By:
/s/ PAUL PENEPENT
     
 
Name:
Paul Penepent
 
Title:
Head Financial Reporting and Accounting
       
 

Novartis

NYSE:NVS

NVS Rankings

NVS Latest News

NVS Latest SEC Filings

NVS Stock Data

293.76B
1.92B
0%
7.05%
0.23%
Drug Manufacturers - General
Healthcare
Link
Switzerland
Basel